GlassScriptPhysician profile
Angelo M Fernandes
NPI 1316980071
$4,988.85
in general payments reported to CMS, 2019-2025
25 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $889 · 2021: $1,088 · 2022: $1,249 · 2023: $283 · 2024: $296 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,699.35 | 2019-2025 | |
| Covidien LP | $494.37 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.10 | 2021-2022 | |
| Redhill Biopharma INC. | $264.59 | 2020-2023 | Aemcolo, Talicia |
| Madrigal Pharmaceuticals | $255.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $246.68 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $220.07 | 2019-2022 | |
| Janssen Biotech, INC. | $164.83 | 2022 | |
| Nestle Healthcare Nutrition INC. | $143.86 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $143.52 | 2019-2022 | |
| Celgene Corporation | $136.79 | 2019-2022 | |
| Evoke Pharma, INC. | $124.46 | 2024 | |
| Alcresta Therapeutics, INC. | $113.21 | 2021 | |
| Lilly USA, LLC | $109.47 | 2025 | Omvoh |
| Intuitive Surgical, INC. | $103.62 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $99.50 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $74.94 | 2024 | Fujifilm |
| Takeda Pharmaceuticals U.S.A., INC. | $70.27 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $54.83 | 2022 | |
| Medtronic, INC. | $40.91 | 2022-2024 | Gi Genius |
| Novo Nordisk INC | $34.99 | 2022 | |
| Ironwood Pharmaceuticals, INC | $31.43 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $19.77 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $17.08 | 2020 | |
| Braintree Laboratories, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Fernandes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.